Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3065519 | Journal of Neuroimmunology | 2008 | 8 Pages |
Abstract
To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile. Steroid reduction effects were observed by using tacrolimus, and no serious adverse effects were observed. The culture study showed reduced IL-12, IL-17, IFN-γ, GM-CSF, TNF-α and MIP-1β, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Yutaka Furukawa, Hiroaki Yoshikawa, Kazuo Iwasa, Masahito Yamada,